Dissociated insulinotropic sensitivity to glucose and carbachol in high-fat diet-induced insulin resistance in C57BL/6J mice.
To study islet function following reduced insulin sensitivity, we examined mice of the C57BL/6J strain, the genotype of which carries an increased propensity to develop insulin resistance when metabolically challenged. The mice received either a high-fat diet (58% fat on an energy basis) or a control diet (11% fat) for 12 weeks. The body weight of mice on the high-fat diet increased significantly more than that of mice on the control diet (25.8 +/- 0.4 v 21.3 +/- 0.2 g, P < .001). Already after 1 week on the high-fat diet, a significant hyperglycemia accompanied by hyperinsulinemia had evolved, indicative of insulin resistance. After 12 weeks, plasma glucose levels for high-fat diet-treated mice were 7.5 +/- 0.1 mmol/L, versus 6.5 +/- 0.1 mmol/L in controls (P < .001); corresponding values for plasma insulin were 248 +/- 17 and 104 +/- 7 pmol/L, respectively (P < .001). Mice given a high-fat diet also had elevated levels of total cholesterol, triglycerides, and free fatty acids (FFAs) compared with controls. After 4, 8, and 12 weeks, glucose (2.8, 8.3, or 16.7 mmol/kg) or the cholinergic agonist carbachol (0.16 or 0.53 micromol/kg) was injected intraperitoneally. The insulinotropic response to glucose was not different between the two groups after 4 or 8 weeks, whereas after 12 weeks, glucose-induced insulin secretion was markedly impaired in high-fat diet-treated mice (P < .001). In contrast, after 8 and 12 weeks on a high-fat diet, carbachol-stimulated insulin secretion was potentiated (P < .01), whereas carbachol-stimulated glucagon secretion was not significantly altered. Furthermore, after 12 weeks on the high-fat diet, insulin secretion from isolated islets was impaired at glucose levels of 8.3, 11.1, and 16.7 mmol/L (P < or = .05). Moreover, islet morphology as examined by immunocytochemistry using insulin antibodies and islet innervation, as revealed by immunostaining of tyrosine hydroxylase (TH), neuropeptide Y (NPY), galanin, vasoactive intestinal polypeptide (VIP), and substance P (SP) were unaffected by the high-fat diet for 12 weeks. However, quantitative in situ hybridization showed a 3.5-fold upregulation of insulin gene expression in response to the high-fat diet (P < .001) despite unaltered B-cell mass and pancreatic insulin content. We conclude that as little as 1 week of treatment with a high-fat diet induces insulin resistance in C57BL/6J mice. This is accompanied later by hyperlipemia, potentiated carbachol-stimulated insulin secretion, and increased insulin gene expression but impaired glucose-stimulated insulin secretion. We suggest that after several weeks' duration, insulin resistance is accompanied by enhanced islet sensitivity to cholinergic activation and exaggerated insulin gene expression, whereas the failing islet sensitivity to glucose represents decompensation.
Ahrén
B
B
Department of Medicine, Lund University, Malmö, Sweden.
Simonsson
E
E
Scheurink
A J
AJ
Mulder
H
H
Myrsén
U
U
Sundler
F
F
D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D001835:Body Weight / Q000502:physiology; D002217:Carbachol / Q000494:pharmacology*; D002784:Cholesterol / Q000097:blood; D004041:Dietary Fats / Q000494:pharmacology*; D004435:Eating / Q000502:physiology; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005260:Female; D019084:Fluorescent Antibody Technique, Indirect; D019004:Galanin / Q000032:analysis / Q000378:metabolism; D015870:Gene Expression; D005838:Genotype; D005934:Glucagon / Q000097:blood; D005947:Glucose / Q000032:analysis / Q000494:pharmacology*; D007150:Immunohistochemistry; D017403:In Situ Hybridization; D007328:Insulin / Q000097:blood / Q000235:genetics / Q000378:metabolism; D007333:Insulin Resistance / Q000502:physiology*; D007515:Islets of Langerhans / Q000737:chemistry / Q000378:metabolism / Q000502:physiology; D051379:Mice; D008810:Mice, Inbred C57BL; D018721:Muscarinic Agonists / Q000494:pharmacology*; D009478:Neuropeptide Y / Q000032:analysis / Q000378:metabolism; D013373:Substance P / Q000032:analysis / Q000378:metabolism; D014280:Triglycerides / Q000097:blood; D014660:Vasoactive Intestinal Peptide / Q000032:analysis / Q000378:metabolism
D001786:Blood Glucose; D004041:Dietary Fats; D005230:Fatty Acids, Nonesterified; D007328:Insulin; D018721:Muscarinic Agonists; D009478:Neuropeptide Y; D014280:Triglycerides; D013373:Substance P; D014660:Vasoactive Intestinal Peptide; D019004:Galanin; D002217:Carbachol; D005934:Glucagon; D002784:Cholesterol; D005947:Glucose